Andrew Calam

Andrew Calam has worked in the pharmaceutical industry since 2000. Andrew started as an AMS analyst at Xceleron, then moved to Charles River Laboratories as a Preclinical Project Manager (Business Co-ordinator). In 2007, they joined Aptuit as a Preclinical Project Manager, then QuintilesIMS as a Clinical Project Manager in 2008. In 2011, they moved to PRA Health Sciences where they were a Clinical Project Manager delivering phase II/III clinical trials. In 2012, they joined Medpace as a Director and Associate Director of Clinical Project Management. In 2017, they became the Director of Clinical Operations at NuCana plc, and in 2021 they became the Executive Director of Clinical Development at Syneos Health. In 2023, they were appointed as the Vice President of Clinical Operations at Epsilogen Ltd.

Andrew Calam attended the University of Leeds from 1994 to 1997, where they earned a degree in Environmental Science with a focus on Chemistry. Prior to that, they attended Pocklington School from 1987 to 1994.